HOXA11 and cervical carcinoma: Considering favorable efficacy in immune checkpoint inhibitors (especially PD‐1/PD‐L1 inhibitors) achieved in treating cervical cancer,40 our study also assessed the expression status of CTLA4, PD‐1, and PD‐L1 in cervical cancer patients grouped by different expression of HOXA1, HOXA10, and HOXA11.